Academy Provides Input on CMS’s Proposed Rule for End-Stage Renal Disease

09/01/2022 - In comments submitted to the Centers for Medicare and Medicaid Services on its proposed rule on payment and the Quality Improvement Program for End Stage Renal Disease services, the Academy shared its support for the conversion of the Hypcercalcemia clinical measure to a clinical measure in assessing treatment of End Stage Renal Disease.

Hypercalcemia outliers can be beyond the clinician's ability to impact, and thus a reporting measure provides a more appropriate, fair, and clinically meaningful data point. In addition, the Academy underscored its support for the screening for food insecurity and other social determinants of health among these patients.

Read the Academy's comments.